preventive-medicine-2018-posters-abstracts

28 / 32

Preventive Medicine 2018 Journal of Preventive Medicine
ISSN: 2572-5483 Page 77
July 16-17, 2018
London, UK
9th Edition of International Conference on
Preventive Medicine
& Public Health
Background: Hemophilia is an inherited bleeding disorder
caused by a deficiency of either factor VIII (hemophilia A) or
IX (hemophilia B). Treatment with intravenous replacement
of these factors and blood carries the risk of transfusion
transmitted viral infections. We performed this study to
estimate the prevalence and seroconversion rates and identify
risk groups of hepatitis C (HCV), hepatitis B (HBV) and human
immunodeficiency virus (HIV) infections among hemophilia
patients in Baghdad City, Iraq, 2016.
Methods: We conducted this cross sectional study by reviewing
records of all hemophilia patients resided in Baghdad in 2016
and registered and received treatment in the four hemophilia
centers in Baghdad. All hemophilia patients are annually
screened for anti-HCV antibody, HBsAg and HIV antibodies.
Positive samples are sent for confirmation at the Central Public
Health Laboratory and the results are reported in the patients’
records.
Results: The total number of registered hemophilia patients in
Baghdad in 2016 was 639. There were 150 (22.9%) patients
with HCV infection, six (0.9%) with HBV infection, and only
one patient (0.2%) had HIV infection. The seroconversion
rate for HCV was 8/1000 and for HBV was 1.7/1000. The
median period between birth and acquiring HCV infection was
17 (IQR=24) years, and for HBV was 11.8 (IQR=9.4) years.
Binary analysis, revealed the following statistically significant
risk factors (P<0.05) for acquiring viral hepatitis infection:
age, severity of hemophilia, presence of inhibitors, type of
treatment, number of treatment products used and presence
of target joints. After applying logistic regression analysis, the
significant independent risk factors were: age (14-18years:
OR=4.03; 95%CI: 1.25-12.94), (19-44 years: OR=18.8; 95%CI:
6.69-52.85), (≥45 years: OR=5.18; 95%CI: 1.01-26.58) and
severe hemophilia (OR=6.25; 95%CI: 1.27-31.25).
Conclusions: Despite screening of blood and blood factors,
HBV and HCV infections still occurring in hemophilia patients.
Closer monitoring of transfused blood and ensue vaccination
of all hemophilia patients for HBV are recommended.
Prevalence and seroconversion of viral hepatitis B and C
and HIV among hemophilia patients in Baghdad, Iraq, 2016
Kamal A Kadhim and Faris Lami
University of Baghdad, Iraq
J Prev Med 2018, Volume 3
DOI: 10.21767/2572-5483-C1-003